UnitedHealth Group Incorporated (UNH): Among Billionaire Ken Fisher's Healthcare Stock Picks with Massive Upside Potential
The healthcare industry, an essential component of global well-being and economic resilience, is undergoing significant changes. The industry, which is thought to account for more than 10% of the world's GDP, is set to enter a new era characterized by demographic shifts, digital innovation, and regulatory realignment. Stakeholders in the life sciences, diagnostics, and healthcare services ecosystem face a conundrum as of 2025: stability is threatened by ongoing financial strain, growing operational complexity, and geopolitical risks, despite the abundance of growth opportunities.
Healthcare earnings in the U.S. are still under pressure. EBITDA as a percentage of national health spending has dropped by 150 basis points since 2019, which has a significant impact on both payers and providers, according to McKinsey. The World Health Organization projects that there will be a 10-million-person shortage of healthcare workers worldwide by 2030, limited reimbursement growth, and high inflationary prices. At the same time, digital transformation has gained importance. According to Deloitte, 90% of executives in global health systems anticipate a faster adoption of digital technology, and over 70% of them intend to increase operational efficiency in 2025.
Artificial intelligence (AI) is at the heart of this change. AI, which was once aspirational, is now a disruptive force that improves everything from medical diagnosis to hospital logistics. AI is seen by EU institutions as essential to the modernization of public health. The European Health Data Space (EHDS), which will be launched in 2025, and the European Commission's 2024 AI Act aim to guarantee that AI technologies are reliable and safe, while facilitating access to high-quality, interoperable health data. These frameworks provide patients and developers with legal protection by simplifying liability standards for flawed AI systems, in conjunction with the revised Product Liability Directive.
However, issues remain. Integrating AI into clinical operations necessitates consistent funding, cultural acceptance, and regulatory clarity. Bias in data, ethical considerations, and the complexity of agentic AI solutions—tools that work autonomously to perform multi-step healthcare processes—require careful management. Despite these challenges, practical applications are gaining traction: AI is currently used in early sepsis identification, breast cancer screening, and pharmaceutical R&D, with the potential to shorten medication development timelines and improve patient outcomes.
Meanwhile, recent geopolitical developments are casting a shadow on global healthcare supply networks. In April 2025, President Donald Trump announced substantial tariffs, including a 10% baseline and targeted taxes on medical devices, which might disrupt access to vital inputs like diagnostic tools and protective equipment. 'What Trump unveiled Wednesday is stupid, wrong, arrogantly extreme, and ignorant trade-wise,' said billionaire investor Ken Fisher in a harsh indictment of the proposal. Furthermore, Morningstar and Fitch analysts warn of rising expenses for hospitals, which are already dealing with low margins and restricted pricing options.
These changes—technological, legislative, and geopolitical—occur against a backdrop of cautious optimism. While GDP growth in the United States is predicted to drop from 2.7% in 2024 to 1.5% in 2025, the healthcare industry remains strong. As AI integration deepens, policy clarity emerges, and investment cycles reset, the industry may be poised for a new era of growth.
To create our list of Billionaire Ken Fisher's 10 Healthcare Stock Picks with Massive Upside Potential, we looked at Ken Fisher's Q4 2024 13F SEC filings to find healthcare stocks in his portfolio. We then chose the ten stocks with the highest upside potential based on average analyst price forecasts, as of the time of writing this article. The equities were then sorted in ascending order of predicted upside. This strategy highlights the most promising healthcare investments in Fisher's existing portfolio. Furthermore, hedge fund sentiment was also laid out for these stocks, as of Insider Monkey's Q4 2024 database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().
A senior healthcare professional giving advice to a patient in a clinic.
UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx are the four main business sectors of UnitedHealth Group Incorporated (NYSE:UNH), which is headquartered in Eden Prairie, Minnesota. The company offers a wide range of pharmaceutical care services, healthcare services, data analytics, and health benefit plans, both domestically and abroad.
Due to unforeseen difficulties in its Medicare Advantage (MA) businesses, UnitedHealth Group Incorporated (NYSE:UNH) updated its full-year adjusted EPS outlook to $26–$26.50 per share in the first quarter of 2025, which concluded on March 31. UnitedHealthcare's MA margins suffered as care activity increased twice as quickly as first predicted, particularly in physician and outpatient services. A more complicated patient mix and lower-than-expected reimbursement for new patients from insurance, leaving specific areas, caused Optum Health to face a revenue shortfall at the same time. Although implementing the new CMS risk adjustment model has been challenging, the company is making efforts to enhance clinician involvement and streamline processes for more precise evaluations.
Notwithstanding these obstacles, UnitedHealth Group Incorporated (NYSE:UNH) maintained its $450–$455 billion consolidated revenue forecast for 2025, bolstered by better-than-expected results from Optum Rx and UnitedHealthcare. With a 3% rise in scripts as a result of new customer acquisitions and excellent retention, Optum Rx's sales increased 14% year over year to surpass $35 billion.
In 2025, Optum Health anticipates adding 650,000 more patients to value-based care models, and UnitedHealth Group Incorporated (NYSE:UNH) is on track to serve an additional 800,000 Medicare Advantage members. Strong momentum in the Medicaid and commercial areas, supported by expanded services and state partnerships, was also recognized by the firm.
UnitedHealth Group Incorporated (NYSE:UNH) is committed to reaching its long-term EPS growth goal of 13%–16%, with a focus on digital engagement, operational efficiency, and technology-driven care delivery. Both income and growth-oriented investors should continue to keep an eye on UnitedHealth Group, which holds a significant position in Ken Fisher's stock portfolio, valued at $1.7 billion.
Overall, UNH ranks 4th on our list of billionaire Ken Fisher's healthcare stock picks with massive upside potential. While we acknowledge the potential of these companies, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than UNH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Why Resideo (REZI) Stock Is Trading Up Today
What Happened? Shares of home automation and security solutions provider Resideo Technologies (NYSE:REZI) jumped 12.9% in the afternoon session after an upgrade from Morgan Stanley, which raised its rating on the stock to Overweight from Equal-Weight. The investment bank boosted its price target to $35 from a previous $24. The upgrade was driven by several positive developments, including Resideo's strong second-quarter results, which surpassed the high end of guidance and marked the best organic revenue growth in 15 quarters. Additionally, analysts highlighted the recent cancellation of a "longstanding and complex" indemnification agreement with Honeywell. This move is seen as removing a significant structural barrier for investors and creating a clearer path to what Morgan Stanley estimates could be approximately $3 in earnings power. The company's plan to separate its ADI Global distribution business in 2026 was also noted as a potential catalyst for unlocking shareholder value. Is now the time to buy Resideo? Access our full analysis report here, it's free. What Is The Market Telling Us Resideo's shares are quite volatile and have had 17 moves greater than 5% over the last year. But moves this big are rare even for Resideo and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 6 days ago when the stock gained 7.5% on the news that the company reported record second-quarter financial results that beat analyst expectations and raised its full-year guidance. The company posted record revenue of $1.94 billion, a 22% increase from the previous year, and adjusted earnings per share of $0.66. These figures surpassed Wall Street's forecasts. While Resideo recorded a net loss of $825 million, this resulted from a one-time expense to end an agreement with Honeywell. Investors appeared to focus on the strong operational performance, as both its Products and Solutions and ADI segments achieved organic revenue growth. In a sign of confidence, the company also lifted its full-year 2025 financial outlook and announced plans to spin off its ADI business segment. Resideo is up 37% since the beginning of the year, and at $31.21 per share, has set a new 52-week high. Investors who bought $1,000 worth of Resideo's shares 5 years ago would now be looking at an investment worth $2,255. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Why Hubbell (HUBB) Stock Is Up Today
What Happened? Shares of electrical and electronic products company Hubbell (NYSE:HUBB) jumped 3.2% in the afternoon session after it agreed to acquire DMC Power, a provider of electrical grid components, for $825 million in cash. DMC Power provides critical connectors and tooling for utility substation and transmission markets. Hubbell's management stated the deal expands its presence in attractive markets, driven by growing power demand from datacenter buildouts and the need to upgrade aging infrastructure. The acquisition is expected to close by the end of 2025 and begin contributing to Hubbell's adjusted earnings per share in 2026. Supporting the stock's move was a broader rally in the Industrials sector, fueled by a favorable inflation report which raised hopes for a Federal Reserve interest rate cut. After the initial pop the shares cooled down to $432.24, up 3.5% from previous close. Is now the time to buy Hubbell? Access our full analysis report here, it's free. What Is The Market Telling Us Hubbell's shares are not very volatile and have only had 7 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 14 days ago when the stock dropped 3.2% on the news that the company reported mixed second-quarter financial results, where a miss on revenue overshadowed a strong earnings beat. The electrical products manufacturer posted revenue of $1.48 billion, which fell short of analysts' consensus estimates of $1.51 billion. This top-line miss appeared to concern investors more than the company's otherwise strong bottom-line performance. Hubbell reported adjusted earnings of $4.93 per share, significantly surpassing Wall Street expectations. Furthermore, the company raised its full-year earnings guidance to a range of $17.65 to $18.15 per share. Despite the positive earnings and improved outlook, the market's reaction suggested that the slowdown in sales growth weighed heavily on sentiment. Hubbell is up 2.9% since the beginning of the year, and at $432.24 per share, it is trading close to its 52-week high of $472.12 from November 2024. Investors who bought $1,000 worth of Hubbell's shares 5 years ago would now be looking at an investment worth $2,939. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
DDD Q2 Deep Dive: Cost Actions Offset Revenue Decline as Tariffs Disrupt Demand
3D printing company 3D Systems (NYSE:DDD) fell short of the market's revenue expectations in Q2 CY2025, with sales falling 16.3% year on year to $94.84 million. Its non-GAAP loss of $0.07 per share was 54.8% above analysts' consensus estimates. Is now the time to buy DDD? Find out in our full research report (it's free). 3D Systems (DDD) Q2 CY2025 Highlights: Revenue: $94.84 million vs analyst estimates of $95.78 million (16.3% year-on-year decline, 1% miss) Adjusted EPS: -$0.07 vs analyst estimates of -$0.16 (54.8% beat) Adjusted EBITDA: -$4.41 million vs analyst estimates of -$13.67 million (-4.6% margin, 67.8% beat) Operating Margin: -16.2%, up from -23.3% in the same quarter last year Market Capitalization: $225.7 million StockStory's Take 3D Systems' results in Q2 reflected ongoing challenges from weakened customer capital spending and tariff uncertainty, but the market reacted positively as the company delivered significant improvements in cost control and profitability measures. Management attributed the 16% year-over-year sales decline primarily to customers delaying new production capacity investments amid volatile tariffs and global economic uncertainty. CEO Jeffrey Graves highlighted that sequential revenue excluding the divested software business grew 8%, pointing to stabilization and the early benefits of strategic restructuring and operational efficiencies. In particular, cost reductions and in-sourcing initiatives helped narrow operating losses and strengthen margins. Looking ahead, 3D Systems' guidance is shaped by continued focus on cost alignment, new product launches, and sector-specific growth opportunities in medical and aerospace markets. Management expects ongoing margin improvement through further operational streamlining and automation, while highlighting the ramp-up of FDA-cleared dental products and expansion in MedTech as drivers for future growth. CEO Jeffrey Graves noted, 'Our top priority is to align our costs with current market conditions in order to move to positive cash flow in 2026,' emphasizing disciplined investment in high-ROI R&D and targeted commercialization efforts despite ongoing macro headwinds. Key Insights from Management's Remarks Management saw Q2 performance shaped by aggressive restructuring, sector-specific product momentum, and the impact of tariffs on customer spending decisions. Cost restructuring accelerated: 3D Systems implemented broad cost reduction actions, including process automation and consolidation of facilities, targeting over $85 million in annualized savings by mid-2026. These moves have already yielded a 27% year-over-year reduction in operating expenses and improved margins, though management cautioned about timing risks related to facility subleasing. Healthcare segment highlights: The MedTech business, encompassing orthopedic solutions, surgical guides, and point-of-care services, grew 13% year-over-year and 16% sequentially. Management cited strong demand for personalized medical devices, particularly for above-the-neck trauma and cancer applications, as a key factor in the segment's resilience. Dental launches and market expansion: The company rolled out its NextDent Jetted Denture Solution, an FDA-cleared product targeting the U.S. market for dental prosthetics. Management sees this as a significant growth opportunity, with early purchase orders and plans for expanded regulatory approvals globally in the coming year. Aerospace and defense momentum: The Aerospace business nearly doubled its annualized revenues, driven by application wins in both the U.S. and Europe. 3D Systems' metal printing platforms have gained traction in high-reliability markets such as aerospace, defense, and AI infrastructure, supporting the company's "3P" strategy (process, parts, printers). Tariffs and CapEx delays: Customers remain hesitant to invest in new printing capacity due to ongoing tariff volatility, causing delays in printer sales but increasing demand for limited-quantity part production. Management is using this period to bridge customers from process development through small-batch production until capital spending resumes. Drivers of Future Performance Management expects near-term results to be shaped by disciplined cost execution, new product commercialization in healthcare, and ongoing macroeconomic and tariff-related headwinds. Margin improvement focus: The company aims to reach positive cash flow in 2026 by further reducing operating expenses, streamlining back-office functions, and consolidating global manufacturing. Operational efficiency gains from in-sourcing and automation are expected to offset rising component costs due to tariffs. Healthcare and dental product scaling: Expansion of MedTech offerings and ramp-up of the NextDent denture solution are seen as primary growth drivers. Management expects regulatory approvals and broader market penetration in dental to increase healthcare revenue mix and support sustainable growth. Tariff and CapEx uncertainty: Persistent uncertainty around tariffs continues to delay large capital equipment purchases by customers, particularly in industrial markets. While this creates near-term headwinds for printer sales, management is leveraging its ability to provide limited-run parts and services as a bridge, with the expectation that demand for new equipment will rebound once the tariff environment stabilizes. Catalysts in Upcoming Quarters In the coming quarters, StockStory analysts will closely monitor (1) the pace of cost reductions and whether operating expenses reach management's targeted range, (2) the commercial uptake and regulatory progress of the NextDent Jetted Denture Solution in both the U.S. and international markets, and (3) sustained growth in MedTech and Aerospace revenues despite ongoing macro headwinds. Execution on facility consolidation and visibility into customer CapEx recovery will also serve as key indicators of future performance. 3D Systems currently trades at $2.25, up from $1.75 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it's free). Now Could Be The Perfect Time To Invest In These Stocks When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
